Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin By Ogkologos - February 23, 2026 159 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-905/EV-303 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR ‘A significant step forwards’ – treating patients with advanced biliary tract... March 30, 2021 FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma December 5, 2025 Five Questions With…Linda. April 7, 2022 Time to take on 9 new Cancer Grand Challenges March 8, 2023 Load more HOT NEWS Mom Fighting Breast Cancer Says Her Haunted House Is Something To... Hiding in plain sight: How we can use immune cells to... Bjorn Saven: “By supporting early career researchers to do their jobs... FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for...
